← Back to Clinical Trials
Recruiting NCT07522931

NCT07522931 Systematic Anatomical Description of the Female Pelvic Retroperitoneum in Cadavers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07522931
Status Recruiting
Phase —
Sponsor Hospital Universitari de Bellvitge
Condition Pelvic Anatomy
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2026-11-14
Primary Completion 2027-09-28

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Anatomical Dissection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2026-11-14 with a primary completion date of 2027-09-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational descriptive cadaveric study aims to describe the main anatomical relationships of the female pelvic retroperitoneum using standardized anatomical dissection. Adult female cadavers obtained from an institutional body donation program will undergo pelvic retroperitoneal dissection. Ten predefined anatomical relationships involving the ureter, pelvic vessels and nerves will be evaluated using a standardized anatomical checklist. Anatomical variability will be described for each item. Standardized photographs will also be obtained to develop an anatomical atlas for educational purposes.

Eligibility Criteria

Inclusion Criteria: * Female cadavers from an institutional body donation program * Age ≥ 18 years at time of death * Adequate preservation of pelvic and abdominal retroperitoneal structures * Anatomical integrity allowing identification of the pelvic ureter, iliac vessels and their main branches, obturator nerve, and other structures included in the anatomical checklist. * Availability of both hemipelves for comparative analysis * Authorization for research use according to institutional body donation regulations Exclusion Criteria: * Male cadavers * Prior major pelvic or abdominal surgery significantly altering retroperitoneal anatomy (e.g., hysterectomy, lymphadenectomy, vascular surgery) * History of pelvic or abdominal radiotherapy * Advanced pelvic or abdominal malignancy with retroperitoneal involvement * Severe trauma affecting pelvic or abdominal anatomy * Poor preservation or significant tissue degradation * Absence of one or both hemipelves * Advanced pregnancy at time of death

Contact & Investigator

Central Contact

Jorge Garcia Fernandez Principal Investigator, Gynecologist

✉ jorgarciafernan@gmail.com

📞 +34622595644

Principal Investigator

Jorge García Fernández, Gynecologist

PRINCIPAL INVESTIGATOR

Hospital Universitari de Bellvitge

Frequently Asked Questions

Who can join the NCT07522931 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Pelvic Anatomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07522931 currently recruiting?

Yes, NCT07522931 is actively recruiting participants. Contact the research team at jorgarciafernan@gmail.com for enrollment information.

Where is the NCT07522931 trial being conducted?

This trial is being conducted at Barcelona, Spain, Barcelona, Spain.

Who is sponsoring the NCT07522931 clinical trial?

NCT07522931 is sponsored by Hospital Universitari de Bellvitge. The principal investigator is Jorge García Fernández, Gynecologist at Hospital Universitari de Bellvitge. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology